Loading publications…
The last 5 uploaded publications
Design and Endpoints of Clinical Trials in Hepatocellular Carcinoma
Josep M. Llovet, Adrian M. Di Bisceglie, Jordi Bruix, Barnett S. Kramer, Riccardo Lencioni, Andrew X. Zhu, Morris Sherman, Myron Schwartz, Michael T. Lotze, Jayant A. Talwalkar, Gregory J. Gores (2008). Design and Endpoints of Clinical Trials in Hepatocellular Carcinoma. JNCI Journal of the National Cancer Institute, 100(10), pp. 698-711, DOI: 10.1093/jnci/djn134.
Article145 days agoEASL-EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma European Association for the Study of the Liver ⇑ , European Organisation for Research and Treatment of Cancer
Josep M. Llovet, Michel Ducreux, Riccardo Lencioni, Adrian M. Di Bisceglie, Jean‐François Dufour, Tim F. Greten, Éric Raymond, Tania Roskams, Vincenzo Mazzaferro, Jordi Bruix, Massimo Colombo, Andrew X. Zhu (2012). EASL-EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma European Association for the Study of the Liver ⇑ , European Organisation for Research and Treatment of Cancer.
Article145 days agoRamucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial
Andrew X. Zhu, Yoon‐Koo Kang, Chia‐Jui Yen, Richard S. Finn, Peter R. Galle, Josep M. Llovet, Éric Assenat, Giovanni Brandi, Marc Pracht, Ho Yeong Lim, Kun‐Ming Rau, Kenta Motomura, Izumi Ohno, Philippe Merle, Bruno Daniele, Dong Bok Shin, Guido Gerken, Christophe Borg, Jean‐Baptiste Hiriart, Takuji Okusaka, Manabu Morimoto, Yanzhi Hsu, P. Abada, Masatoshi Kudo (2019). Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet Oncology, 20(2), pp. 282-296, DOI: 10.1016/s1470-2045(18)30937-9.
Article145 days agoImmunotherapies for hepatocellular carcinoma
Josep M. Llovet, Florian Castet, Mathias Heikenwälder, Mala K. Maini, Vincenzo Mazzaferro, David J. Pinato, Eli Pikarsky, Andrew X. Zhu, Richard S. Finn (2021). Immunotherapies for hepatocellular carcinoma. Nature Reviews Clinical Oncology, 19(3), pp. 151-172, DOI: 10.1038/s41571-021-00573-2.
Article145 days agoPhase Ib Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular Carcinoma
Richard S. Finn, Masafumi Ikeda, Andrew X. Zhu, Max W. Sung, Ari David Baron, Masatoshi Kudo, Takuji Okusaka, Masahiro Kobayashi, Hiromitsu Kumada, Shuichi Kaneko, Marc Pracht, K. G Mamontov, Tim Meyer, Tomoki Kubota, Corina E. Dutcus, Kenichi Saito, Abby B. Siegel, Leonid Dubrovsky, Kalgi Mody, Josep M. Llovet (2020). Phase Ib Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular Carcinoma. Journal of Clinical Oncology, 38(26), pp. 2960-2970, DOI: 10.1200/jco.20.00808.
Article145 days ago